Journals / art / 2021 / Cilt: 36 - Sayı: 2

Baculoviral inhibitor of apoptosis family of proteins repeat-containing 5 gene methylation status in peripheral blood mononuclear cells and plasma survivin levels in patients with Behçet’s disease

Journal
art
Pages
185–191
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was no significant correlation between survivin plasma levels and BD activity.Conclusion: Our study did not show any evidence of association between the alteration in the BIRC5 gene methylation, survivin production, and apoptosis dysregulation in BD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to evaluate the baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) gene methylation in the peripheral blood mononuclear cells (PBMCs) in patients with Behçet’s disease (BD) compared to healthy controls and the association of survivin with BD activity.Patients and methods: A cross-sectional study was conducted on 43 BD patients (22 males, 21 females; mean age 36.6±10.1 years; range, 18 to 66 years) and 44 age- and sex-matched healthy controls (23 males, 21 females; mean age 35.4±7.5 years; range, 18 to 61 years) between August 2019 and December 2019.
📊
Key Findings & Data:Sample size was calculated guided by taking into account the difference of 1.5 units between the mean expression of BIRC5 gene in the BD and control groups, as well as considering α=0.5 and power=80%.
💡
Conclusion & Impact:There was no significant correlation between survivin plasma levels and BD activity.Conclusion: Our study did not show any evidence of association between the alteration in the BIRC5 gene methylation, survivin production, and apoptosis dysregulation in BD.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to evaluate the baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) gene methylation in the peripheral blood mononuclear cells (PBMCs) in patients with Behçet’s disease (BD) compared to healthy controls and the association of survivin with BD activity.Patients and methods: A cross-sectional study was conducted on 43 BD patients (22 males, 21 females; mean age 36.6±10.1 years; range, 18 to 66 years) and 44 age- and sex-matched healthy controls (23 males, 21 females; mean age 35.4±7.5 years; range, 18 to 61 years) between August 2019 and December 2019. Sample size was calculated guided by taking into account the difference of 1.5 units between the mean expression of BIRC5 gene in the BD and control groups, as well as considering α=0.5 and power=80%. We assessed the methylation status of the BIRC5 gene in PBMCs of BD and control groups by methylation-specific polymerase chain reaction (MS-PCR). Plasma levels of survivin were measured by enzyme-linked immunosorbent assay.Results: Oral aphthous ulcer, genital ulcer, and skin lesions were the most common clinical manifestations in BD group. MS-PCR showed that the deoxyribonucleic acid samples of BD and control groups were not different in methylated and unmethylated areas and alleles were heterozygote. No significant difference was observed in the plasma levels of survivin in BD (98.86±25.5 pg/mL) and control (118.16±37.4 pg/mL) groups. There was no significant correlation between survivin plasma levels and BD activity.Conclusion: Our study did not show any evidence of association between the alteration in the BIRC5 gene methylation, survivin production, and apoptosis dysregulation in BD.

🔖

Cite This Article

PAHLAVAN, Y., KHABBAZI, A. (2021). Baculoviral inhibitor of apoptosis family of proteins repeat-containing 5 gene methylation status in peripheral blood mononuclear cells and plasma survivin levels in patients with Behçet’s disease. art, Cilt: 36 - Sayı: 2, 185–191. https://ajindex.com/articles/351620

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Tong B, Liu X, Xiao J, Su G. Immunopathogenesis of Behcet’s Disease. Front Immunol 2019;10:665
  2. Khabbazi A, Rashtchizadeh N, Ghorbanihaghjo A, Hajialiloo M, Ghojazadeh M, Taei R, et al. The status of serum vitamin D in patients with active Behcet’s disease compared with controls. Int J Rheum Dis 2014;17:430-4
  3. Malek Mahdavi A, Khabbazi A, Yaaghoobian B, Ghojazadeh M, Agamohammadi R, Kheyrollahiyan A, et al. Cigarette smoking and risk of Behcet’s disease: a propensity score matching analysis. Mod Rheumatol 2019;29:633-9
  4. Meguro A, Inoko H, Ota M, Katsuyama Y, Oka A, Okada E, et al. Genetics of Behçet disease inside and outside the MHC. Ann Rheum Dis. 2010;69:747-54
  5. Dehghanzadeh R, Babaloo Z, Sakhinia E, Khabazi A, Shanehbandi D, Sadigh-Eteghad S, et al. IL-27 Gene Polymorphisms in Iranian Patients with Behcet’s Disease. Clin Lab 2016;62:855-61
  6. Hosseini A, Shanehbandi D, Estiar MA, Gholizadeh S, Khabbazi A, Khodadadi H, et al. A Single Nucleotide Polymorphism in the FOXP3 Gene Associated with Behçet’s Disease in an Iranian Population. Clin Lab 2015;61:1897-903
  7. Gravina G, Wasén C, Garcia-Bonete MJ, Turkkila M, Erlandsson MC, Töyrä Silfverswärd S, et al. Survivin in autoimmune diseases. Autoimmun Rev 2017;16:845-55
  8. Pahlavan Y, Kahroba H, Samadi N, Karimi A, Ansarin K, Khabbazi A. Survivin modulatory role in autoimmune and autoinflammatory diseases. J Cell Physiol 2019;234:19440-50
  9. Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A. Expression of Bcl-2 in inflammatory sites from patients with active Behçet’s disease. Mediators Inflamm 1999;8:101-6
  10. Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A. Levels of soluble Fas/APO-1 in patients with Behçet’s disease. Mediators Inflamm 1998;7:111-4
  11. Wakisaka S, Takeba Y, Mihara S, Takeno M, Yamamoto S, Sakane T, et al. Aberrant Fas ligand expression in lymphocytes in patients with Behçet’s disease. Int Arch Allergy Immunol 2002;129:175-80
  12. Baris YS, Yildiz L, Sentürk N, Kandemir B. Fas (CD95) and bcl-2 expression in active skin lesions of Behçet’s disease. J Eur Acad Dermatol Venereol 2005;19:569-72
  13. Yang P, Chen L, Zhou H, Zhong H, Wang H, Huang X, et al. Resistance of lymphocytes to Fasmediated apoptosis in Behçet’s disease and Vogt- Koyangi-Harada syndrome. Ocul Immunol Inflamm 2002;10:47-52
  14. Yang P, Ji L, Zhou H, Huang X, Xie C, Jin H, et al. Disturbed expression of Fas/FasL on CD4(+) and CD8(+)T cells in Behcet’s disease, Vogt-Koyanagi- Harada syndrome, and idiopathic ant